# Comparison of Losartan Associated With Indapamide Versus Hyzaar® in the Hypertension Treatment

Study · id `cardio:ct-nct01620788` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01620788](<https://clinicaltrials.gov/study/NCT01620788>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01620788

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 636 participants.

## Technical summary

Registry record NCT01620788. Randomized; no masking; primary purpose treatment. Start 2019-11-27 (actual); primary completion 2023-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 636 participants (planned count; ClinicalTrials.gov record NCT01620788, source copy `cardio:ctgov-nct01620788-2022-07-27`, retrieved 2026-10-26)
- Started: 2019-11-27 (actual) (ClinicalTrials.gov record NCT01620788, source copy `cardio:ctgov-nct01620788-2022-07-27`, retrieved 2026-10-26)
- Primary completion: 2023-07 (anticipated) (ClinicalTrials.gov record NCT01620788, source copy `cardio:ctgov-nct01620788-2022-07-27`, retrieved 2026-10-26)
- Completion: 2023-10 (anticipated) (ClinicalTrials.gov record NCT01620788, source copy `cardio:ctgov-nct01620788-2022-07-27`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT01620788, source copy `cardio:ctgov-nct01620788-2022-07-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "SUSPENDED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01620788-2022-07-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Losartan Associated With Indapamide Versus Hyzaar® in the Hypertension Treatment
- Condition: Hypertension
- Intervention (Drug): Indapamide / Losartan
- Intervention (Drug): Indapamide / Losartan
- Intervention (Drug): Hyzaar®
- Intervention (Drug): Hyzaar®
- Lead sponsor: EMS
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: c8b148b6f8303272e25b9c806a8c9dd1c092217e9194a572a11741d0d1db73aa
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
